Management of Dyskinesia
For levodopa-induced dyskinesia in Parkinson's disease, reduce the individual levodopa dose and add amantadine; for antipsychotic-induced tardive dyskinesia, discontinue the offending medication if clinically feasible or switch to an atypical antipsychotic. 1
Levodopa-Induced Dyskinesia
Immediate Management Strategy
The FDA label explicitly states that dyskinesias may require dosage reduction 1. This is your first-line intervention for peak-dose dyskinesia—the most common type occurring at maximum levodopa plasma levels.
Treatment algorithm:
- Peak-dose dyskinesia: Reduce individual levodopa doses and fractionate dosing throughout the day. Add amantadine as the primary adjunctive medication 2, 3
- Off-period/wearing-off dystonia: Increase levodopa frequency or add dopamine agonists. Consider baclofen or botulinum toxin injections for focal dystonia 2
- Diphasic dyskinesia (occurring during rising and falling levodopa levels): Most difficult to treat—requires careful dose fractionation, though many patients ultimately need deep brain stimulation 2
Advanced Interventions
When medication adjustments fail, globus pallidus interna (GPi) deep brain stimulation is the most effective intervention for severe dyskinesia, showing superior efficacy compared to subthalamic nucleus (STN) stimulation specifically for dyskinesia control 3. A 2025 network meta-analysis of 85 RCTs involving 13,826 patients ranked GPi-DBS highest (SUCRA = 97.4%) for reducing dyskinesia severity 3.
Alternative advanced options in descending order of efficacy:
- Levodopa-carbidopa intestinal gel infusion (SUCRA = 89.7%)
- STN-DBS (SUCRA = 89%)
- Pallidotomy (SUCRA = 84.9%)
- Extended-release amantadine/ADS-5102 (SUCRA = 82.9%, though higher adverse event rates) 3
Critical Pitfall
Do not delay initiating levodopa therapy to prevent dyskinesia—this outdated practice is no longer recommended. Dyskinesia development correlates with disease duration, not cumulative levodopa exposure 4. Delaying levodopa unnecessarily compromises quality of life without preventing dyskinesia.
Antipsychotic-Induced Tardive Dyskinesia
Management Hierarchy
Because there is no specific pharmacological treatment for tardive dyskinesia other than discontinuing the medication, prevention and early detection are paramount 5.
When tardive dyskinesia occurs:
If patient is in full remission and any medication change risks relapse: Continue current dose 5
In all other cases: Attempt to lower the antipsychotic dose or switch to an atypical antipsychotic 5
For severe, refractory cases: Bilateral pallidal deep brain stimulation has proven effective and safe for severe tardive dyskinesia 6
Prevention Protocol
The guidelines mandate specific monitoring:
- Obtain baseline abnormal movement assessment before starting antipsychotics (use Abnormal Involuntary Movement Scale) 5
- Assess for dyskinesias every 3-6 months during ongoing therapy 5
- Provide adequate informed consent regarding tardive dyskinesia risk 5
Important Distinction
Withdrawal dyskinesia (occurring with gradual or sudden cessation) almost always resolves over time, whereas tardive dyskinesia may persist even after discontinuation 5. Up to 50% of youth receiving neuroleptics may experience some form of tardive or withdrawal dyskinesia 5.
Acute Dystonic Reactions
For acute dystonia from antipsychotics (sudden spastic muscle contractions, oculogyric crisis):
- Treat immediately with anticholinergic or antihistaminic medications 5
- Risk factors: young age, male gender, high-potency agents 5
- Laryngeal dystonia is life-threatening—requires emergent treatment 7, 5
Prophylactic antiparkinsonian agents should be considered for patients at high risk for acute dystonias or with prior dystonic reactions, particularly when medication compliance is a concern 5